30 closest matches · ranked by relevance
Lower Urinary Tract Symptoms · Bladder Outlet Obstruction
Primary: Change From Baseline to End of Treatment in Detrusor Pressure at Maximum Flow Rate (PdetQmax) — -1.69; -7.84; -6.69 cmH2O
Overactive Bladder
Primary: Urinary Frequency — 10.5; 11; 12; 8.5 urinations
Lower Urinary Tract Symptoms · Bladder Outlet Obstruction
Primary: Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax) — -0.33; 0.07; 0.30 mL/sec
Overactive Bladder · Urinary Urge Incontinence · Overactive Bladder Syndrome
Primary: Change in Overactive Bladder Questionnaire Long Form Score (Symptoms Severity Sub-scale)(OAB-Q LF) — -31.2; -39.5 units on a scale
Overactive Bladder · Urinary Tract Infection
Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants
Benign Prostatic Hyperplasia
Primary: Improvement in the AUA Symptom Score Index by 30% From Baseline Within the First 12 Weeks After Injection. — 46; 50 participants — p=<0.05
Overactive Bladder · Urinary Urge Incontinence · Urinary Bladder, Neurogenic
Primary: Change in Bladder Injection Pain — 5; 4; 5 units on a scale — p=0.94
Benign Prostatic Hyperplasia · Lower Urinary Track Symptoms
Primary: American Urologic Association Symptom Score (AUASS) — 18.66; 14.16 score on a scale
Benign Prostatic Hyperplasia
Primary: Change From Baseline in the Total International Prostate Symptom Score (IPSS) at Week 12 — 21.8; 21.5; -6.3; -5.6 Score on a scale
Overactive Bladder
Primary: 24-hour Voiding Frequency — 9.1; 9.5 voids per 24-hour day — p=.001
BPH
Primary: Primary Outcome; International Prostate Symptom Score Changes Between 4 Groups Compared to Baseline After 12 mo Treatment — 13.0; 12.0; 10.6; 13.4 score — p=<0.05
Urge Urinary Incontinence · Overactive Bladder
Primary: Change in Urge Urinary Incontinence (UUI) Episodes — -3.13; -3.15; -3.32; -3.25 Mean change in UUI episodes from baselin
Overactive Bladder
Primary: Percentage of Participants Who Achieve a 100% Reduction in Urinary Incontinence Episodes — 32.0; 7.2 percentage of participants
Neurogenic Bladder · Lower Urinary Tract Symptoms · Overactive Bladder
Primary: Willingness to Repeat Procedure — 9.16; 9.34; 9.73; 9.67 units on a scale — p=0.57
Urinary Urge Incontinence
Primary: Change in Maximum Capacity at Cystoscopy Between Baseline and 6 Month Follow-up — -97.5; 64.1 mL — p=.016
Overactive Bladder · Urinary Incontinence
Primary: Change From Study Baseline in Number of Episodes of Urinary Incontinence in Treatment Cycle 1 — 4.86; 5.23; 4.38; -3.10 Incontinence Episodes
Overactive Bladder
Primary: Participant Discomfort Related to BTX-A Injection — 3.2; 3.6 score on a scale — p=0.21
Lower Urinary Tract Symptoms · Benign Prostatic Hyperplasia
Primary: Number of Participants With Adverse Events (AEs) — 499; 255; 12; 69 participants
Overactive Bladder
Primary: Mean Change of the Total Frequency Per 3 Days — -4.64; -0.19 Frequency per 3 days
Urinary Bladder, Overactive · Urinary Incontinence
Primary: Change From Baseline in Daily Average Number of Urinary Incontinence Episodes — -2.99; -0.42 incontinence episodes per day — p=<.0001
Mixed Urinary Incontinence · Stress Urinary Incontinence · Urgency Incontinence
Primary: Number of Participants With Self-reported Mixed Urinary Incontinence Symptoms — 31; 34 Participants
Overactive Bladder
Primary: Change From Baseline at Week 12 in the Average Number of Micturition Episodes Per Day — -2.04; -1.30 Micturitions per day — p=<0.0001
Benign Prostatic Hyperplasia · Lower Urinary Tract Symptoms
Primary: Change From Baseline to End of Treatment in Total International Prostate Symptom Score — -5.4; -6.2; -7.0; -6.5 units on a scale — p=0.001
Urinary Incontinence · Overactive Bladder With Urinary Incontinence
Primary: Stage 2: Change From Baseline in the Average Number of Urinary Incontinence Episodes (UIEs) Per Day — -2.72; -1.62; -0.89; -1.52 episodes per day — p=0.0845
Urinary Incontinence, Urge
Primary: Number of Urge Urinary Incontinence (UUI) Episodes — -3.25; -3.89 UUI episodes
Urinary Retention
Primary: Persistent Retention — 29; 21 participants
Benign Prostatic Hyperplasia
Primary: Change From Baseline in International Prostate Symptom Score (IPSS) at Week 12 — 21.3; 20.2; 21.5; 20.7 Score on a scale
Overactive Bladder
Primary: Number of Participants With Any Serious Adverse Event, and Treatment Emergent Adverse Event (>5%) — 2; 3; 17; 3 Participants
Overactive Bladder · Detrusor Instability · Detrusor Hyperreflexia
Primary: Median Number of Incontinent Episodes During 24 Hours — 4; 2; 4 number of incontinent episodes — p=0.004
Bladder Outlet Obstruction
Primary: IPSS Obstructive — 9.1; 7.5; 8.4; 7.9 units on a scale